![]() ![]() The resulting material was put through dialysis and sterile filtering before being freeze dried. student in Christman's lab, solved this issue by putting the liquid precursor of the hydrogel through a centrifuge, which allowed for sifting out bigger particles and keeping only nano-sized particles. ![]() But the particle size in the hydrogel was too big to target leaky blood vessels. Researchers in Christman's lab started with the hydrogel they developed, which was proven to be compatible with blood injections as part of safety trials. By contrast, hydrogel injected via a catheter remains in specific locations and doesn't spread out. One advantage of the new biomaterial is that it gets evenly distributed throughout damaged tissue, because it's infused or injected intravenously. in Christman's group in the Shu Chien-Gene Lay Department of Bioengineering. "We sought to design a biomaterial therapy that could be delivered to difficult-to-access organs and tissues, and we came up with the method to take advantage of the bloodstream - the vessels that already supply blood to these organs and tissues," said Martin Spang, the paper's first author, who earned his Ph.D. This meant developing a biomaterial that could be infused into a blood vessel in the heart at the same time as other treatments such as angioplasty or a stent, or injected intravenously. ![]() The team wanted to develop a treatment that could be administered immediately after a heart attack. But because it needs to be injected directly into heart muscle, it can only be used a week or more after a heart attack - sooner would risk causing damage because of the needle-based injection procedure. Results from a successful phase 1 human clinical trial were reported in fall 2019. The gel forms a scaffold in damaged areas of the heart, encouraging new cell growth and repair. In previous studies, the team led by Christman developed a hydrogel made from the natural scaffolding of cardiac muscle tissue, also known as the extracellular matrix (ECM), that can be injected into damaged heart muscle tissue via a catheter. "As an interventional cardiologist, who treats patients with coronary artery disease and congestive heart failure on a daily basis, I would love to have another therapy to improve patient outcomes and reduce debilitating symptoms." Reeves, a physician in the UC San Diego Division of Cardiovascular Medicine. "Coronary artery disease, acute myocardial infarction, and congestive heart failure continue to be the most burdensome public health problems affecting our society today," said Dr. After a heart attack, scar tissue develops, which diminishes muscle function and can lead to congestive heart failure. There are an estimated 785,000 new heart attack cases in the United States each year, and there is no established treatment for repairing the resulting damage to cardiac tissue. 29 issue of Nature Biomedical Engineering. The team, which brings together bioengineers and physicians, presented their findings in the Dec. "It's a new approach to regenerative engineering."Ī study on the safety and efficacy of the biomaterial in human subjects could start within one to two years, Christman added. "This biomaterial allows for treating damaged tissue from the inside out," said Karen Christman, a professor of bioengineering at the University of California San Diego, and the lead researcher on the team that developed the material. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |